HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy
IntroductionTumor immunotherapy has revolutionized cancer treatment, particularly through the use of immune checkpoint inhibitors targeting the PD-L1/PD-1 axis. While PD-L1 expression on tumor cells is an established predictive biomarker for therapeutic response, emerging evidence highlights the imp...
Saved in:
| Main Authors: | Valeria Spadotto, Chiara Ripamonti, Andrea Ghiroldi, Elisabetta Galbiati, Pietro Pozzi, Roberta Noberini, Tiziana Bonaldi, Christian Steinkühler, Gianluca Fossati |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1546939/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
by: Ching Lin, et al.
Published: (2025-12-01) -
The role of HDAC6 in fibrosis: a novel and effective therapy strategy
by: Liangliang Zheng, et al.
Published: (2025-07-01) -
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP‐43 proteinopathies
by: Cheng‐Chun Wu, et al.
Published: (2020-05-01) -
From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs
by: Rebecca L McIntyre, et al.
Published: (2019-08-01) -
CCT196969 inhibits TNBC by targeting the HDAC5/RXRA/ASNS axis to down-regulate asparagine synthesis
by: Qiong Yuan, et al.
Published: (2025-08-01)